Nonetheless, it can be concluded that low-dose IL2 therapy in conjunction with respective conservative therapy has proved to be a superior treatment modality for both SLE and RA, has limited adverse effects as compared to conventional therapy alone, and has a similar therapeutic application and safety profile in both autoimmune diseases. The gene discussed is IL2; the disease is rheumatoid arthritis.